Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance.
Sridaran D, Chouhan S, Mahajan K, Renganathan A, Weimholt C, Bhagwat S, Reimers M, Kim EH, Thakur MK, Saeed MA, Pachynski RK, Seeliger MA, Miller WT, Feng FY, Mahajan NP.
Sridaran D, et al. Among authors: miller wt.
Nat Commun. 2022 Nov 14;13(1):6929. doi: 10.1038/s41467-022-34724-5.
Nat Commun. 2022.
PMID: 36376335
Free PMC article.